Literature DB >> 10910914

The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure.

R A Ariëns1, H Philippou, C Nagaswami, J W Weisel, D A Lane, P J Grant.   

Abstract

Factor XIII on activation by thrombin cross-links fibrin. A common polymorphism Val to Leu at position 34 in the FXIII A subunit is under investigation as a risk determinant of thrombosis. Because Val34Leu is close to the thrombin cleavage site, the hypothesis that it would alter the function of FXIII was tested. Analysis of FXIII subunit proteolysis by thrombin using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and high-performance liquid chromatography showed that FXIII 34Leu was cleaved by thrombin more rapidly and by lower doses than 34Val. Mass spectrometry of isolated activation peptides confirmed the predicted single methyl group difference and demonstrated that the thrombin cleavage site is unaltered by Val34Leu. Kinetic analysis of activation peptide release demonstrated that the catalytic efficiency (k(cat)/K(m)) of thrombin was 0.5 for FXIII 34Leu and 0.2 (micromol/L)(-1) x sec(-1) for 34Val. Presence of fibrin increased the catalytic efficiency to 4.8 and 2.2 (micromol/L)(-1) x sec(-1), respectively. Although the 34Leu peptide was released at a similar rate as fibrinopeptide A, the 34Val peptide was released more slowly than fibrinopeptide A but more quickly than fibrinopeptide B generation. Cross-linking of gamma- and alpha-chains appeared earlier when fibrin was incubated with FXIII 34Leu than with 34Val. Fully activated 34Leu and 34Val FXIII showed similar cross-linking activity. Analysis of fibrin clots prepared using plasma from FXIII 34Leu subjects by turbidity and permeability measurements showed reduced fiber mass/length ratio and porosity compared to 34Val. The structural differences were confirmed by electron microscopy. These results demonstrate that Val34Leu accelerates activation of FXIII by thrombin and consequently affects the structure of the cross-linked fibrin clot.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10910914

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Factor XIII Val34Leu polymorphism and gamma-chain cross-linking at the site of microvascular injury in healthy and coumadin-treated subjects.

Authors:  A Undas; B Brzezinska-Kolarz; K Brummel-Ziedins; J Musial; A Szczeklik; K G Mann
Journal:  J Thromb Haemost       Date:  2005-09       Impact factor: 5.824

Review 2.  Newly-Recognized Roles of Factor XIII in Thrombosis.

Authors:  James R Byrnes; Alisa S Wolberg
Journal:  Semin Thromb Hemost       Date:  2016-04-07       Impact factor: 4.180

3.  Factor XIII activity mediates red blood cell retention in venous thrombi.

Authors:  Maria M Aleman; James R Byrnes; Jian-Guo Wang; Reginald Tran; Wilbur A Lam; Jorge Di Paola; Nigel Mackman; Jay L Degen; Matthew J Flick; Alisa S Wolberg
Journal:  J Clin Invest       Date:  2014-07-01       Impact factor: 14.808

4.  Characteristics of fibrin formation and clot stability in individuals with congenital type IIb protein C deficiency.

Authors:  J H Foley; L Ferris; K E Brummel-Ziedins
Journal:  Thromb Res       Date:  2012-01-13       Impact factor: 3.944

5.  Effects of introducing fibrinogen Aalpha character into the factor XIII activation peptide segment.

Authors:  Madhavi A Jadhav; Giulia Isetti; Toni A Trumbo; Muriel C Maurer
Journal:  Biochemistry       Date:  2010-04-06       Impact factor: 3.162

6.  Risk for early pregnancy loss by factor XIII Val34Leu: the impact of fibrinogen concentration.

Authors:  Astrid Dossenbach-Glaninger; Mick van Trotsenburg; Christian Oberkanins; Johanna Atamaniuk
Journal:  J Clin Lab Anal       Date:  2013-11       Impact factor: 2.352

7.  Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus.

Authors:  E J Dunn; H Philippou; R A S Ariëns; P J Grant
Journal:  Diabetologia       Date:  2006-03-16       Impact factor: 10.122

8.  Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.

Authors:  H M H Spronk; T Padro; J E Siland; J H Prochaska; J Winters; A C van der Wal; J J Posthuma; G Lowe; E d'Alessandro; P Wenzel; D M Coenen; P H Reitsma; W Ruf; R H van Gorp; R R Koenen; T Vajen; N A Alshaikh; A S Wolberg; F L Macrae; N Asquith; J Heemskerk; A Heinzmann; M Moorlag; N Mackman; P van der Meijden; J C M Meijers; M Heestermans; T Renné; S Dólleman; W Chayouâ; R A S Ariëns; C C Baaten; M Nagy; A Kuliopulos; J J Posma; P Harrison; M J Vries; H J G M Crijns; E A M P Dudink; H R Buller; Y M C Henskens; A Själander; S Zwaveling; O Erküner; J W Eikelboom; A Gulpen; F E C M Peeters; J Douxfils; R H Olie; T Baglin; A Leader; U Schotten; B Scaf; H M M van Beusekom; L O Mosnier; L van der Vorm; P Declerck; M Visser; D W J Dippel; V J Strijbis; K Pertiwi; A J Ten Cate-Hoek; H Ten Cate
Journal:  Thromb Haemost       Date:  2018-01-29       Impact factor: 5.249

9.  The inflammatory response is influenced by FXIII VAL 34 LEU polymorphism in a human LPS model.

Authors:  Florian M Kovar; Claudia L Marsik; Bernd Jilma; Christine Mannhalter; Christian Joukhadar; Oswald F Wagner; Georg Endler
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

10.  Genes influencing coagulation and the risk of aneurysmal subarachnoid hemorrhage, and subsequent complications of secondary cerebral ischemia and rebleeding.

Authors:  Ynte M Ruigrok; Arjen J C Slooter; Gabriel J E Rinkel; Cisca Wijmenga; Frits R Rosendaal
Journal:  Acta Neurochir (Wien)       Date:  2009-10-14       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.